Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) Director Troy Cox bought 15,620 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was purchased at an average cost of $9.52 per share, for a total transaction of $148,702.40. Following the completion of the transaction, the director directly owned 15,620 shares in the company, valued at approximately $148,702.40. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Maplight Therapeutics Trading Down 6.6%
Shares of Maplight Therapeutics stock opened at $14.03 on Friday. The business’s fifty day moving average price is $30.98 and its 200 day moving average price is $24.96. Maplight Therapeutics, Inc. has a twelve month low of $9.10 and a twelve month high of $40.43. The stock has a market capitalization of $597.96 million and a P/E ratio of -0.34.
Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). As a group, sell-side analysts predict that Maplight Therapeutics, Inc. will post -5.22 EPS for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on MPLT
Hedge Funds Weigh In On Maplight Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of MPLT. Strs Ohio acquired a new stake in Maplight Therapeutics in the fourth quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Maplight Therapeutics during the fourth quarter valued at approximately $70,000. New York State Common Retirement Fund acquired a new position in shares of Maplight Therapeutics during the fourth quarter worth $93,000. MetLife Investment Management LLC acquired a new position in shares of Maplight Therapeutics during the fourth quarter worth $172,000. Finally, Walleye Capital LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $205,000.
About Maplight Therapeutics
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Featured Articles
- Five stocks we like better than Maplight Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
